Genentech says that the biosimilar company benefited from its proprietary information, and a hearing is scheduled for December 13, 2018.
Last month, former Genentech employees were charged with conspiring to steal trade secrets to assist biosimilar developer JHL Biotech in developing its products. Last week, Genentech filed a motion in the United States district court for the Northern District of California, seeking an injunction to block JHL from making and selling potential biosimilars. Genentech says that the biosimilar company benefited from its proprietary information. A hearing is scheduled for December 13, 2018.
The company will request that the court block JHL from “making, testing, using, promoting, offering to sell, marketing, commercializing, or selling biologics, therapeutics, drugs, and/or products of any kind that utilize, embody, or were developed, in whole or in part, with the benefit or use of any of Genentech’s trade secret information."
Although not among the parties indicted for the alleged theft of trade secrets, JHL co-founder, co-chairman, president and CEO Racho Jordanov and co-founder, COO, and general manager Rose Lin were listed as defendants by Genentech.
On October 25, a federal grand jury indicted 3 former Genentech employees, Xanthe Lam, Allen Lam, and James Quach, as well as John Chan, a former JHL formulation scientist. The 4 allegedly stole trade secrets over the course of 5 years related to the biopharmaceutical dornase alfa (Pulmozyme) and some of Roche’s top-selling cancer drugs: rituximab (Rituxan), trastuzumab (Herceptin), and bevacizumab (Avastin).
According to the indictment, the stolen information includes proprietary analytical methods for ensuring drug safety and efficacy, processes for developing and testing products for quality purposes, and procedures and protocols for calibrating and maintaining manufacturing equipment and facilities.
Xanthe Lam, a principal scientist at the Roche Holding AG unit from 1986 until 2017, allegedly downloaded, collected, and transferred the proprietary information to her husband, Allen Lam, and others at JHL. She also allegedly secretly consulted for JHL while still employed at Genentech.
If the indicted defendants are found guilty, Xanthe Lam, Allen Lam, and Chan face as long as 10 years in prison. Quach could face as many as 5 years.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.